FreeTrials & Tribulations Engineering-level molecular diagnosis: A necessity for cancer treatment—and for a successful Moonshot July 21, 2023Vol.49 No.29By Michael P. Castro
Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you July 14, 2023Vol.49 No.28By Matthew Bin Han Ong
Can ctDNA be used as an endpoint for cancer drug development?Friends collaboration to present initial results July 11 July 07, 2023Vol.49 No.27By Matthew Bin Han Ong
In the era of immunotherapy and targeted therapies, ODAC focuses on dose optimization in children June 23, 2023Vol.49 No.25By Jacquelyn Cobb
Trials & Tribulations We need better communication to enable patients to thrive in cancer survivorship June 23, 2023Vol.49 No.25By Lauren Ghazal and Fumiko L. Chino
An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.” June 16, 2023Vol.49 No.24By Paul Goldberg
Study at ASCO plenary:Radiation can be omitted for some rectal cancer patients June 09, 2023Vol.49 No.23By Jacquelyn Cobb
ComboMATCH trial—a collaboration across NCI and NCTN groups—matches patients with combination therapy trials based on tumor biology June 02, 2023Vol.49 No.22By Jacquelyn Cobb
Cisplatin, carboplatin shortage prompts rationing of lifesaving drugs—patients will die May 26, 2023Vol.49 No.21By Paul Goldberg
Trials & Tribulations Continuous temperature tracking helps manage infection risk after CAR T-cell therapy May 05, 2023Vol.49 No.18By Ruth Phillips
